Using tACS to treat depression

Efficacy and Safety of Transcranial Alternating Current Stimulation for Depression: a Multicenter Randomized Controlled Trial Study

This study is testing whether a new non-invasive treatment called tACS can help adults with major depression feel better.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 72 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: Ruijin Hospital (Academic / other)
• Locations: 2 sites (Shanghai and 1 other locations)
• Trial ID: NCT06891326 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the efficacy and safety of transcranial alternating current stimulation (tACS) as a non-invasive treatment for major depression. It involves a multicenter randomized controlled trial design, where participants will be randomly assigned to receive either active tACS or sham stimulation. The study aims to recruit 72 participants aged 18 to 65 who have been diagnosed with depression, ensuring that they meet specific inclusion criteria. The trial will assess the outcomes while maintaining blinding for both participants and study staff.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 to 65 with a clinical diagnosis of depression and a HDRS-17 score of 8 or higher.

Not a fit: Patients with other psychotic disorders, neurological diseases, or those who have undergone invasive brain surgeries may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a safer and more cost-effective option for patients suffering from depression.

How similar studies have performed: Previous studies on tACS for depression have shown mixed results, making this approach both relevant and potentially novel.

Eligibility criteria

Inclusion Criteria:

1. Clinical diagnosis of depressive disorder;
2. Age ranges between 18 and 65 years;
3. HDRS-17 score equals to or above 8;
4. No medical history/Under stable antidepressant treatment in one month;

Exclusion Criteria:

1. Combination of other psychotic disorders and neurological diseases;
2. History of invasive brain surgeries;
3. Non-invasive neurostimulation treatments within 3 months;
4. Physical condition that may endanger patients' safety during the study.

Where this trial is running

Shanghai and 1 other locations

• Ruijin Hospital affiliated to Shanghai JiaoTong University School of Medicine — Shanghai, China (Not_yet_recruiting)
• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, China (Recruiting)

Study contacts

• Study coordinator: Yunhao Wu

Conditions Depression Disorders; tACS; depression